Analysis of the Efficacy, Safety and Continuation Rate of Abatacept in Elderly Patients with Rheumatoid Arthritis

Mayumi Matsuda¹, Yu Funakubo Asanuma², Noritsune Kouzu³ and Toshihide Mimura², ¹Department of Rheumatology and Applied Immunology, Saitama Medical University, Moroyama-machi, Japan, ²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ³Saitama Medical University, Moroyama, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Abatacept, Efficient, Elderly, rheumatoid arthritis (RA) and safety

Session Information

Date: Tuesday, November 7, 2017

Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The elderly rheumatoid arthritis (RA) patients have declined physical performances and various complications. The efficacy of the biological DMARDs may decrease in elderly RA patients because not enough dosage of MTX could be used for them, due to some concerns such as risks of the infection increasing. The purpose of this study was to examine the efficacy, safety and continuation rate of abatacept(ABT) in elderly patients with RA.

Methods: sixty-three RA patients who had received ABT in Saitama Medical University Hospital between Oct. 2010 and May 2016 were divided into 2 groups. One was 64 years old and under (n=31), the other was 65 years old and over (n=32). In these 2 groups, we examined the retrospective evaluation of the patients’ background, disease activity, decline in physical performance, reduction of methotrexate (MTX) or prednisolone (PSL) dose, safety and continuation rate of ABT.

Results: In the patients background (younger group/elderly group), mean age of onset (46/60 year-old), rate of female (83.9/84.4%), naïve rate of biological DMARDs (51.6/28.1%), mean disease duration (7.9/12.1 years), rate of MTX use (64.5/37.5% p=0.045), rate of PSL use (64.5/87.5% p=0.041), mean dose of MTX (5.4/3.1mg/week), mean dose of PSL (5.0/5.1mg/day), DAS28-ESR4 (5.53/5.84)、and HAQ (1.13/1.67 p=0.046), positive rate of RF (74.2/93.8% p=0.043) were observed. The elderly group showed higher HAQ (p=0.046) than the younger group. In effectiveness, DAS28-ESR4 and HAQ significantly decreased in both groups for the observational period of one year after initiation of ABT therapy (P<0.05). ABT therapy did not reduce the dose of MTX for one year, while reduction of the dose of PSL was observed in both groups. There were no significant differences in the continuation rate between the younger (87.1%) and the elderly group (75.0%). The cancellation reason of ABT (younger group/elderly group) were due to adverse events (6.5/12.5％), ineffective (6.5/6.3％), remission (0.0/3.1％) one year after ABT started.

Conclusion: The ABT treatment in the elderly RA patients was suggested useful as much as in the younger patients regarding the effectiveness, the reduction of PSL dose, and the continuation rate.

Disclosure: M. Matsuda, None; Y. F. Asanuma, None; N. Kouzu, None; T. Mimura, Abbvie, 5,Astellas, 5,Eisai, 5,Janssen Pharmaceutica Product, L.P., 5,Novartis Pharmaceutical Corporation, 5,Ono Pharma, 5,Pfizer Inc, 5,Sanofi-Aventis Pharmaceutical, 5,Takeda Pharmaceutical, 5,Tanabe-Mitsubishi Pharma, 5.

To cite this abstract in AMA style:

Matsuda M, Asanuma YF, Kouzu N, Mimura T. Analysis of the Efficacy, Safety and Continuation Rate of Abatacept in Elderly Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/analysis-of-the-efficacy-safety-and-continuation-rate-of-abatacept-in-elderly-patients-with-rheumatoid-arthritis/. Accessed .

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analysis-of-the-efficacy-safety-and-continuation-rate-of-abatacept-in-elderly-patients-with-rheumatoid-arthritis/